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Network meta-analysis (NMA) that simultaneously addresses
the comparative effectiveness and/or safety of multiple
interventions through combining direct and indirect estimates
of effect is rapidly gaining popularity and influence.1-6Although
NMA approaches appear attractive,6-8 application of their results
requires understanding the quality of the evidence. By quality
of evidence, we mean the degree of confidence or certainty one
can place in estimates of treatment effects.
NMA is sufficiently new that terminology differs between
authors and continues to evolve. Box 1 presents a glossary of
terms used in this article.
Rationale for an approach to rate the
quality of evidence from NMA
Recently, several articles have provided guidance regarding
identification of the evidence for a NMA,9 statistical aspects of
conducting NMA,10-17 and critical appraisal and interpretation
of published NMA.18 19 Few of these, however, provide explicit
guidance on how to rate the quality of the evidence.4 20 21
Reports of NMAs often describe the risk of bias of trials
included in a NMA (such as method of randomisation,
concealment of random allocation, masking, etc).22-24 For
example, a recent NMA compared the effects of coronary artery
bypass grafting, various stents, and medical treatment on
mortality, myocardial infarction, and the need for
revascularisation among patients with stable coronary artery
disease. The authors stated that appropriate methods of
concealment of random allocation were reported for 71 trials
(71%).25 Fifty six trials (56%) reported blind adjudication of
clinical outcomes, and for 69 trials (69%) data from intention
to treat analyses were available. Although such an assessment
of risk of bias describes the entire body of evidence (that is, all
trials contributing evidence to the NMA), it does not
acknowledge that the risk of bias is likely to differ across the
comparisons of the network.1 For example, the risk of bias of
studies comparing sirolimus eluting stents versus medical
treatment may be considerably less than the risk of bias of
studies comparing coronary artery bypass grafting with medical
treatment. In addition, risk of bias is only one determinant of
quality of evidence. Our confidence in effect estimates will, for
instance, also decrease if there are large differences in results
from study to study (for example, some studies suggest benefit,
but others suggest harm) or if results are imprecise (that is, small
numbers of patients and resulting wide confidence intervals,
see box 2). Furthermore, the popular approach of treatment
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Box 1: Glossary of terms (in order they appear in the text)
Ranking—Ordering of treatments according to their relative effectiveness. The first ranked treatment is most likely to be the most effective
treatment with respect to a particular outcome compared with the other treatments in the network
Direct estimates—Estimate of effect provided by a head-to-head comparison (such as trials of A versus B when A v B is the comparison
of interest)
Indirect estimates—Estimate of effect provided by two or more head-to-head comparisons that share a common comparator (such as
trials of A v C and trials of B v C when A v B is the comparison of interest)
Network—A collection of trials of alternative interventions for a clinical condition that allow, through direct and indirect comparisons,
calculation of the relative effects of all treatment versus placebo or standard care, and versus one another, on a particular outcome (for
example, fig 1⇓)
Loops—Two or more head-to-head comparisons that contribute to an indirect estimate. First order loops are those loops that involve
only a single additional intervention. For example, if we are interested in A versus B, the direct estimates of A versus C and B versus C
constitute a first order loop (see red solid line in fig 2⇓). A second order loop would involve two other interventions (such as A v C, C v
D, and D v B; see green and blue dashed lines in fig 2⇓). Higher order loops involve additional interventions
Intransitivity—Differences in study characteristics that may modify treatment effect in the direct comparisons (such as A v C and B v C)
that form the basis for the indirect estimate of effect of the comparison of interest (A v B), and thus bias the indirect assessment of A
versus B. Factors that may modify treatment effects include differing patient characteristics; differing co-interventions; differing extent
to which interventions of interest are optimally administered; differing comparators; and differences in measurement of outcome
Heterogeneity—Differences in estimates of effect across studies that assessed the same comparison
Incoherence—Differences between direct and indirect estimates of effect
rankings (for example, probability that coronary artery bypass
grafting is the most effective treatment to lower the risk of
mortality) will result in misleading inferences when most
evidence is low or very low quality, or when evidence
supporting higher ranked treatments (such as coronary artery
bypass grafting) is much lower quality than evidence supporting
lower ranked treatments (such as drug eluting stents). Patients
and clinicians may choose a lower ranked treatment with
supporting evidence they can trust over a higher ranked
treatment with supporting evidence they cannot trust.
The GRADE Working Group and its
approach to rate the quality of evidence
The Grading of Recommendations Assessment, Development
and Evaluation (GRADE) Working Group began in the year
2000 as an informal collaboration of people with an interest in
addressing the shortcomings of present grading systems in health
care. The GRADE Working Group has developed a sensible
and transparent approach to grading quality of evidence (box
2).20 26-31 The goal of this approach is to provide ratings for the
confidence in the estimates of effect for a specific comparison
(such as sirolimus eluting stents v medical treatment) for all
outcomes of importance to patients (such as all-cause mortality,
recurrent angina). If all trials are at low risk of bias; if all
included populations, interventions, and outcomes are applicable
to practice; if trials show similar estimates of treatment effects;
if the effect estimates from meta-analysis are precise (for
example, narrow 95% confidence interval); and if suspicion of
publication bias is low, we will judge the quality of evidence
as high (that is, we can be confident that the true effect lies close
to that of the estimate of the effect). If, however, trials are at
high risk of bias; show inconsistent estimates of effects across
trials; included highly selected patients or used surrogate
outcomes; if the estimates of treatment effect are imprecise; or
if we have a high suspicion of publication bias, we will judge
the evidence as lower quality (that is, the confidence in estimates
of treatment effect is only moderate, low or very low, box 2).
In this paper we describe the GRADE Working Group’s
approach to rating the quality of evidence for specific
comparisons included in a NMA. Discussion of an approach to
rate the confidence in estimates of effect from NMA began at
an international meeting on NMA at Johns Hopkins University
(Baltimore MD, USA)1 and with a face-to-face GRADE
Working Group meeting in 2010 (Keystone CO, USA). An
iterative process includingmore face-to-facemeetings, electronic
conferences, email discussions, and multiple iterations of a draft
manuscript followed. The final meeting took place at a GRADE
Working Group meeting in 2014 (Barcelona, Spain).
TheGRADE four-step approach for rating
the quality of treatment effect estimates
from NMA
Rating the quality of treatment effect estimates from NMA
requires best estimates from direct, indirect, and NMA
(combined direct + indirect) evidence, as well as quality ratings
for the direct and indirect comparisons. We propose the
following four steps to assess the quality of treatment effect
estimates from NMA (fig 1⇓):
1. Present direct and indirect treatment estimates for each
comparison of the evidence network. The direct estimate of
effect is provided by a head-to-head comparison (trials of A
v B), and the indirect estimate is provided by two or more
head-to-head comparisons that share a common comparator
(for example, we infer the effects of A v B from trials of A
v C and trials of B v C).
2. Rate the quality of each direct and indirect effect estimate.
3. Present the NMA estimate for each comparison of the
evidence network.
4. Rate the quality of each NMA effect estimate.
Example used for illustration
Weuse a recent NMA to illustrate the application of the GRADE
approach. This article will not present details of the underlying
systematic reviews and statistical aspects of the NMA; these
are reported elsewhere.8 In brief, the NMA included randomised
trials that compared drug treatments to prevent fragility fractures
in individuals with or at risk of osteoporosis. The target
population was postmenopausal women at risk of developing
fragility fractures, but a small number of eligible trials enrolled
men or women irrespective of risk. The drug treatments included
bisphosphonates (alendronate, risedronate, zoledronate, and
ibandronate), teriparatide, selective oestrogen receptor
modulators (raloxifene), denosumab, and calcium and/or vitamin
D.
Here, we present the hip fracture outcome data from 40 trials
that included 139 647 participants, of whom 2567 (1.8%) had
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Box 2: GRADE approach for rating the quality of estimates of treatment effect
Goal of
Provides a rating for the quality of the estimates of effect for a specific comparison and a specific outcome
Ratings
High quality (⊕⊕⊕⊕)—We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality (⊕⊕⊕O)—We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect,
but there is a possibility that it is substantially different
Low quality (⊕⊕OO)—Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect
Very low quality (⊕OOO)—We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect
Starting point
If randomised trials form the evidence base the quality rating starts with high. If observational studies form the evidence base the quality rating
starts low. Lack of randomisation typically leads to a initial rating of low
Down rating
The quality rating may be rated down by −1 (serious concern) or −2 (very serious concern) for the following reasons
• Risk of bias (such as failure to conceal random allocation or blind participants28 in randomised controlled trials or failure to adequately control
for confounding in observational studies)
• Inconsistency (such as heterogeneity of estimates of effects across trials29)
• Indirectness (such as surrogate outcomes, study populations or interventions that differ from those of interest,20 or intransitivity;19 for further
explanation see box 3)
• Imprecision (for example, 95% confidence intervals are wide and include or are close to null effect30)
• Publication bias31
Up rating
Rating up is typically applied only to observational studies; the most common reason is for a large or very large effect seen over a short period
of time and altering a clear downward trajectory
Explanations
For reasons of transparency and for better understanding of the ratings, reasons for rating are documented, typically in a summary table’s
footnotes
Box 3: Clarification of GRADE rating down for indirectness
Indirectness, a term established by the GRADE Working Group,20 refers to two different concepts.
One concept relates to differences between the question of interest and the body of evidence that is identified and used to inform the question.
We may rate down the quality for this type of indirectness when patients of interest (as defined by the question) overlap only partly with
patients enrolled in trials (for example, the population of interest is the very elderly, few of who participated in the trials); interventions of
interest differ from those regimens tested in trials (for example, the intensity of anticoagulation control differed in trials compared with the
community setting); or outcomes of interest differ from those measured in trials (for example, trials in diabetes measured blood glucose, a
surrogate endpoint, rather than cardiovascular events).
The second concept on indirectness, particularly relevant for NMA, relates to biased evidence from indirect comparisons. In accordance
with the NMA literature, in this article we refer to this second concept as intransitivity (see box 1 for definition of intransitivity).15 16
a hip fracture. The results presented in this paper are identical
to those of the primary report,8 and we did not perform any new
NMA for this paper. We did, however, apply our new GRADE
approach to rating the quality of evidence of each comparison
(this was not done in the original article). Figure 2⇓ shows the
evidence network for the available direct comparisons.
Step 1: Presenting direct and indirect effect
estimates and 95% CI
Making valid inferences on the basis of a NMA requires
understanding of both the direct and indirect evidence that
contributes to the NMA effect estimates. Several approaches
exist for calculating indirect estimates.12 32 33 For the example
presented here we use a method referred to as node splitting,
which separates evidence on a particular comparison (a “node”)
into direct and indirect estimates of treatment effect.12 For
example, direct evidence for the comparison of alendronate
versus raloxifene in our fracture prevention example shows an
odds ratio of 0.49.8Because the trial directly comparing the two
agents is small, the 95% confidence interval is wide (0.04 to
5.45, fig 1⇓). The indirect evidence (odds ratio 0.53, 95%
confidence interval 0.30 to 0.90) includes a first order loop (first
order loops are those loops that involve only a single additional
intervention, such as vitamin D plus calcium, see red solid line
in fig 2⇓) and second order loops (loops that involve two other
interventions, such as calcium, vitamin D, and placebo, see
green and blue dashed lines in fig 2⇓).
Step 2: Rating of quality of direct and indirect
effect estimates
Investigators rate the quality of evidence separately for direct
and indirect evidence. The confidence estimates for the direct
comparisons involve an application of the GRADE principles
(box 2) to each comparison for which head-to-head trials are
available. For the network of drugs to prevent osteoporotic
fractures, we found seven direct comparisons to warrant high
or moderate confidence and nine direct comparisons to warrant
low or very low confidence (table 1⇓).
Depending on the size and structure of the evidence network,
one, few, or many loops can contribute indirect evidence to the
comparisons of interest. To keep the quality rating of the indirect
evidence manageable, we suggest a focus on first order loops,
which usually contribute most information to the indirect
estimate. To identify the relevant loops a network graph such
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as figure 2⇓ is needed (red solid line represents the first order
loop for the indirect comparison of alendronate v raloxifene).
The rating of the quality of the indirect estimate is then based
on the ratings of the two pairwise estimates (such as A v C and
B vC) that contribute to the indirect estimate of the comparison
of interest (A vB); these ratings can follow established GRADE
guidance.26 For example, when comparing alendronate versus
raloxifene, the comparisons of alendronate versus vitamin D
plus calcium and raloxifene versus vitamin D plus calcium (fig
2⇓, red solid line) create the first order loop. The lower
confidence rating of the two direct comparisons constitutes the
confidence rating of the indirect comparison. In this case, for
both comparisons, the confidence rating is moderate: therefore,
the initial rating of the indirect evidence warrants moderate
confidence.
There is, however an additional issue that may further reduce
confidence in estimates from the indirect comparison:
intransitivity (see box 1). If the trials forming the basis for the
indirect estimate (such as trials of A v C and of B v C) differ in
important ways the likelihood of intransitivity may be high. As
a consequence the indirect estimate of the comparison of interest
(A vB)may be biased. In the presence of intransitivity wewould
rate down further from the lower of the confidence ratings of
the contributing direct comparisons.
Consider, for example, the indirect comparison for risedronate
versus vitamin D plus calcium (fig 2⇓). The trials with placebo
as common comparator provide most of the indirect evidence.
Risedronate was tested in 20 trials for the prevention of fragility
fractures. In half of these trials, patients were using
glucocorticoid treatment or had a chronic disease that might
modify bonemetabolism (such as inflammatory bowel disease).8
This contrasts with the trials of vitamin D plus calcium versus
placebo, in which participants were included only if they did
not take drugs and did not have diseases that modify bone
metabolism.34 As a consequence of these differences between
the trials of risedronate and vitamin D plus calcium versus the
common comparator placebo, we decided to down rate the
indirect comparison of risedronate versus vitaminD plus calcium
for intransitivity.
It is conceivable that a substantial proportion of indirect
comparisons of any NMAwarrant down rating for indirectness
because of these two reasons. Although we suggest a low
threshold for down rating for indirectness, authors should be
explicit and report reasons for down rating in the footnotes of
the table that presents the direct, indirect, and network estimates
of effect. For the network of drugs to prevent osteoporotic
fractures, we found 10 indirect comparisons to be of high or
moderate quality, respectively, and 41 indirect comparisons to
be of low or very low quality, respectively (table 1⇓).
Steps 3 and 4: Presenting and rating of quality
of NMA effect estimates
If only direct or indirect evidence is available for a given
comparison, the network quality rating will be based on that
estimate. When, for a particular comparison, both direct and
indirect evidence are available, we suggest using the higher of
the two quality ratings as the quality rating for the NMA
estimate (for example, moderate quality if quality of the direct
estimate is moderate and quality of the indirect estimate is low).
There are two reasons we have chosen this approach. First, if
direct and indirect estimates are similar (coherent, see box 1),
the lower quality estimate can only bolster the higher (it would
make no sense to add evidence that would lower the quality of
estimates). Second, in general, we expect the higher rated
estimate to be the more precise (and thus dominating) body of
evidence.
In the rarer instances in which the less precise estimate warrants
higher confidence it likely means that there are no other reasons
for down rating that estimate. On the other hand, if the more
precise estimate warrants lower confidence than the less precise
estimate, there must be serious problems (risk of bias,
inconsistency, publication bias, indirectness). If direct and
indirect are coherent, the serious problems with risk of bias in
the lower confidence are unlikely to have biased the results. If
there is serious incoherence then we default to the following
guidance regarding what to do in the presence of incoherence.
The assessment of coherence (others use different terminology
such as inconsistency) addresses the assumption that direct and
indirect evidence are similar enough to be pooled. A commonly
used approach to investigate coherence is to test the statistical
significance of the difference between direct and indirect
estimates.11 12 29 In addition, the magnitude of differences
between the direct and indirect estimates should bear on
addressing incoherence.
Consider table 2⇓, which presents results from a NMA of the
impact of alternative surgical approaches to open tibial fractures
on reoperation (from Foote CJ, Guyatt GH, Vignesh KN, et al
“Systematic review of prospective investigation of surgical
treatment of open tibial shaft fractures (SPRINT review): a
network meta-analysis” submitted for publication). In the
comparison of unreamed versus reamed nailing, the direct
estimate suggests unreamed is superior. The indirect evidence
also suggests unreamed is superior, but the effect is much larger,
the confidence intervals of the two estimates are virtually
non-overlapping, and the statistical test of interaction generates
a P value of 0.02. This suggests major incoherence between
direct and indirect estimates. On the other hand, for the
comparison of unreamed nailing versus external fixation (table
2⇓) we would conclude the results are coherent.
In the face of large incoherence in a particular comparison we
do not advocate discarding or modifying the NMA (for instance,
by excluding the incoherent data) without a strong rationale.
NMA authors can guide users of the NMA in one of two ways.
The first is to focus attention on the direct or indirect estimate
warranting greater confidence, rather than the NMA estimate,
as the best estimate of effect. This is the approach authors used
in the NMA of open tibial fractures. An alternative is to focus
on the NMA estimate but rate down the quality of that estimate
for incoherence (in this example, also for imprecision, thus
leading to a judgment of low quality).
The optimal strategy is likely to depend on the circumstances.
If the difference in quality between the two estimates is large,
and one of the two is of higher quality, the former approach
may be desirable. If the difference in quality between the two
estimates is smaller, and neither is of high quality, using the
NMA estimate and rating down for incoherence may be
preferable.When there is only indirect evidence it is not possible
to assess incoherence.33 In such situations issues regarding
intransitivity may warrant particular attention, and the threshold
for rating down for intransitivity may be lower.
In the example of preventing osteoporotic fractures, table 1⇓
presents the NMA estimates and the final quality ratings. For
most of the comparisons, there is only indirect evidence (such
as alendronate v zoledronate), and the quality rating of the
indirect comparison also represents the quality of the NMA
estimate. For the comparison of vitamin D plus calcium versus
risedronate, direct evidence had very low confidence rating and
contributed substantiallymore to the NMA estimate than indirect
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evidence; therefore, the quality rating for the NMA estimate
was also very low. Across the network, we found three
comparisons (5% of all comparisons) of high quality, 13 (24%)
of moderate quality, 19 (35%) of low quality, and 20 (36%) of
very low quality.
Finally, one further criterion warrants consideration. While
estimates from both direct and indirect may cross a threshold
that warrants rating down for imprecision, the pooled network
estimate, because it is more precise, may not. For example, we
rated down both the direct and indirect comparisons of calcium
versus calcium plus vitamin D for imprecision (table 1⇓). Since
the pooled estimate was more precise, therefore increasing our
confidence that calcium plus vitamin D is more effective than
calcium alone, we did not rate down the NMA estimate for
imprecision.
Variability of quality of treatment effect
estimates and ranking
Quality of estimates can vary greatly across comparisons within
the network. Indeed, in our illustrative example, quality varied
from high to very low (table 1⇓). In making inferences regarding
choice of intervention, recognising the quality of each
comparison is far more valuable than the single risk of bias
assessment across an evidence network typically reported in
most NMA articles.22-25
An example of the necessity for rating the quality of individual
paired comparisons arises from the initial report of the fracture
NMA we present here. Using the standard ranking approach in
NMA, the authors concluded teriparatide had the largest fracture
reduction of the 10 treatments studied (odds ratio 0.42 against
no treatment, table 1⇓) and the highest probability of being
ranked first across the treatments. Our quality ratings of
teriparatide against placebo and other comparators are, however,
low or very low (table 1⇓). Other agents (zoledronate or
denosumab) had high or moderate confidence ratings of
superiority over placebo and over vitamin D plus calcium. The
quality ratings suggest that clinicians and patients seeking a
drug that prevents hip fractures will be better off choosing
zoledronate or denosumab than teriparatide.
What the GRADE guidance adds to
existing NMA guidance documents
A wealth of literature addressing NMA has accumulated over
recent years. For example, Cipriani and colleagues provided
excellent guidance on key statistical aspects of NMA.10 A task
force of the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) published three documents
addressing the conduct and interpretation of NMA as well as a
checklist for critical appraisal of NMA.18 19 35A recent overview
of reporting practices paves the way for an extension of the
PRISMA statement addressing NMA.36
Some of these documents addressed risk of bias for the entire
network or specific comparisons of a NMA.14 18 19 35 Only one,
a more statistically oriented paper, provides guidance on how
to rate the quality of indirect and NMA estimates considering
not only risk of bias but also other criteria that affect confidence
in estimates of effect (box 2 and criteria specific to NMA).21
The four-step approach of the GRADE Working Group fills a
gap by providing guidance to determine quality ratings for each
estimate of effect in a NMA.
Research needs
There are a number of studies that would be useful to refine the
four-step approach presented here. A previous study showed
that inter-rater agreement is high if the raters are familiar with
GRADE and if calibration exercises are done.37 It is important
to conduct inter-rater agreement studies for NMA in order to
identify those aspects of the rating process that require additional
guidance and calibration exercises.Meta-epidemiological studies
addressing the effects of specific criteria (such as intransitivity)
on estimates of effect provided by NMA would be useful to
inform how readily one should down rate the quality.
Finally, we do not currently support the use of weights
(reflecting the amount of information) to decide if the quality
rating of the direct or indirect estimate should determine the
quality of the NMA estimate. Statistical approaches to determine
weights are already incorporated in standard statistical packages.
There is, however, little experience in the interpretation and use
of such weights in different NMA (that may differ by, for
example, their geometry). Studies that inform the optimal use
of weights may lead to a revised approach for generating quality
ratings for NMA estimates.
Conclusion
The GRADE Working Group approach following four steps
highlights the necessity for authors of NMA to present direct,
indirect, and NMA estimates as well as quality ratings for all
direct comparisons. If authors do not present these estimates,
scepticism regarding any inferences from the NMA is warranted.
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Tables
Table 1| Estimates of effects and quality ratings for comparison of drugs to prevent osteoporotic hip fractures
Network meta-analysisIndirect evidenceDirect evidence
Comparison
Quality of
evidence
Odds ratio (95%
credible interval)
Quality of
evidence
Odds ratio (95%
credible interval)
Quality of
evidence
Odds ratio
(95%
confidence
interval)
Very low0.42 (0.10 to 1.82)Very low‡,**0.42 (0.10 to 1.82)——Teriparatide v placebo
High0.50 (0.27 to 0.86)High0.50 (0.27 to 0.86)——Denosumab v placebo
Moderate0.87 (0.63 to 1.22)Low‡,¶0.96 (0.53 to 1.78)Moderate‡0.84 (0.63 to
1.13)
Raloxifene v placebo
High0.50 (0.34 to 0.73)High0.50 (0.33 to 0.74)——Zoledronate v placebo
Low0.48 (0.31 to 0.66)Low**0.54 (0.36 to 0.75)Low*,‡‡0.17 (0.05 to
0.59)
Risedronate v placebo
Very low0.49 (0.21 to 1.20)Very low‡,**0.49 (0.21 to 1.20)——Ibandronate v placebo
Moderate0.45 (0.27 to 0.68)Moderate ¶0.45 (0.27 to 0.68)——Alendronate v placebo
Low1.13 (0.94 to 1.34)Low‡,¶1.08 (0.61; 1.91)Low*,‡1.25 (0.82 to
1.89)
Vitamin D v placebo
Moderate0.81 (0.68 to 0.96)Low**0.54 (0.29 to 0.94)Moderate*0.83 (0.73 to
0.96)
Vitamin D+calcium v placebo
Moderate1.14 (0.82 to 1.59)Moderate¶1.14 (0.82 to 1.59)——Calcium v placebo
Low1.17 (0.24 to 5.54)Low‡,¶1.17 (0.24 to 5.54)——Denosumab v teriparatide
Very low2.05 (0.47 to 9.47)Very low‡,**2.05 (0.47 to 9.47)——Raloxifene v teriparatide
Very low1.18 (0.26 to 5.30)Very low‡,¶,‡‡1.18 (0.26 to 5.30)——Zoledronate v teriparatide
Very low1.12 (0.25 to 4.98)Very low‡,¶,‡‡1.12 (0.25 to 4.98)——Risedronate v teriparatide
Very low1.11 (0.22 to 6.42)Very low‡,**1.11 (0.22 to 6.42)——Ibandronate v teriparatide
Very low1.02 (0.24 to 4.82)Very low‡,**1.02 (0.24 to 4.82)——Alendronate v teriparatide
Very low2.67 (0.63 to 11.97)Very low‡,**2.67 (0.63 to 11.97)——Vitamin D v teriparatide
Low1.92 (0.45 to 8.42)Not estimable††Not estimable††Low*,‡2.00 (0.50 to
8.33)
Vitamin D+calcium v
teriparatide
Very low2.69 (0.63 to 12.23)Very low‡,**2.69 (0.63 to 12.23——Calcium v teriparatide
Low1.76 (0.95 to 3.41)Low‡,¶1.76 (0.95 to 3.41)——Raloxifene v denosumab
Low1.02 (0.54 to 1.93)Low‡,‡‡1.02 (0.54 to 1.93)——Zoledronate v denosumab
Very low0.96 (0.50 to 1.78)Very low‡,**,‡‡0.96 (0.50 to 1.78)——Risedronate v denosumab
Low0.98 (0.36 to 2.79)Low‡,¶0.98 (0.36 to 2.79)——Ibandronate v denosumab
Low0.90 (0.45 to 1.78)Low‡,¶0.90 (0.45 to 1.78)——Alendronate v denosumab
Moderate2.28 (1.28 to 4.16)Moderate¶2.28 (1.28 to 4.16)——Vitamin D v denosumab
Moderate1.64 (0.97 to 2.87)Not estimable††Not estimable††Moderate1.67 (1.02 to
2.70)‡
Vitamin D+calcium v
denosumab
Moderate2.33 (1.25 to 4.40)Moderate¶2.33 (1.25 to 4.40)——Calcium v denosumab
Low0.57 (0.35 to 0.93)Low¶,‡‡0.57 (0.35 to 0.93)——Zoledronate v raloxifene
Very low0.55 (0.31 to 0.84)Very low**,‡‡0.55 (0.31 to 0.84)——Risedronate v raloxifene
Very low0.55 (0.23 to 1.42)Very low‡,**0.55 (0.23 to 1.42)——Ibandronate v raloxifene
Moderate0.51 (0.29 to 0.87)Moderate¶0.53 (0.30 to 0.90)Low§0.49 (0.04 to
5.45)
Alendronate v raloxifene
Low1.30 (0.89 to 1.86)Low**1.30 (0.89 to 1.86)——Vitamin D v raloxifene
Moderate0.94 (0.66 to 1.31)Low¶,‡‡0.96 (0.63 to 1.49)Moderate‡0.88 (0.51 to
1.54)
Vitamin D+calcium v
raloxifene
Very low1.31 (0.83 to 2.06)Very low‡,**1.31 (0.83 to 2.06)——Calcium v raloxifene
Low0.96 (0.56 to 1.49)Low‡‡0.96 (0.56 to 1.49)——Risedronate v zoledronate
Very low0.97 (0.39 to 2.55)Very low‡,¶,‡‡0.97 (0.39 to 2.55)——Ibandronate v zoledronate
Low0.90 (0.51 to 1.51)Low‡,‡‡0.90 (0.51 to 1.51)——Alendronate v zoledronate
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;349:g5630 doi: 10.1136/bmj.g5630 (Published 24 September 2014) Page 7 of 10
RESEARCH METHODS & REPORTING
Table 1 (continued)
Network meta-analysisIndirect evidenceDirect evidence
Comparison
Quality of
evidence
Odds ratio (95%
credible interval)
Quality of
evidence
Odds ratio (95%
credible interval)
Quality of
evidence
Odds ratio
(95%
confidence
interval)
Low2.26 (1.50 to 3.42)Low¶,‡‡2.26 (1.50 to 3.42)——Vitamin D v zoledronate
High1.63 (1.16 to 2.30)Not estimable††Not estimable††High1.64 (1.16 to
2.17)
Vitamin D+calcium v
zoledronate
Low2.29 (1.44 to 3.66)Low¶,‡‡2.29 (1.44 to 3.66)——Calcium v zoledronate
Very low1.02 (0.43 to 2.66)Very low‡,**,‡‡1.02 (0.43 to 2.66)——Ibandronate v risedronate
Very low0.93 (0.54 to 1.62)Very low**,‡‡0.93 (0.54 to 1.62)——Alendronate v risedronate
Very low2.35 (1.63 to 3.76)Very low**,‡‡2.35 (1.63 to 3.76)——Vitamin D v risedronate
Low1.69 (1.27 to 2.54)Low¶,‡‡5.88 (1.79 to 25.00)Very
low*,†,‡
1.92 (0.84 to
4.35)
Vitamin D+calcium v
risedronate
Very low2.39 (1.56 to 4.04)Very low**,‡‡2.39 (1.56 to 4.04)——Calcium v risedronate
Low0.92 (0.34 to 2.32)Low‡,¶0.92 (0.34 to 2.32)——Alendronate v ibandronate
Very low2.32 (0.92 to 5.54)Very low‡,**2.32 (0.92 to 5.54)——Vitamin D v ibandronate
Low1.69 (0.69 to 3.84)Not estimable††Not estimable††Low‡1.72 (0.76 to
3.85)
Vitamin D+calcium v
ibandronate
Very low2.36 (0.92 to 5.87)Very low‡,**2.36 (0.92 to 5.87)——Calcium v ibandronate
Moderate2.54 (1.63 to 4.16)Moderate¶2.38 (1.49 to 3.85)Moderate*3.70 (1.20 to
11.11)
Vitamin D v alendronate
Moderate1.82 (1.24 to 2.90)Moderate¶2.78 (1.14 to 8.33)Moderate*1.59 (1.03 to
2.44)
Vitamin D+calcium v
alendronate
Moderate2.56 (1.57 to 4.34)Moderate¶2.56 (1.54 to 4.35)Very low*,§4.55 (0.47 to
50.00)
Calcium v alendronate
Low0.72 (0.57 to 0.91)Low¶,‡‡0.65 (0.48 to 0.85)Low*,‡1.03 (0.68 to
1.54)
Vitamin D+calcium v vitamin
D
Low1.01 (0.72 to 1.44)Low**1.01 (0.72 to 1.44)——Calcium v vitamin D
Moderate§§1.40 (1.03 to 1.95)Very low‡,**,‡‡3.43 (0.26 to 160.40)Low*,‡1.21 (0.89 to
1.66)
Calcium v calcium+vitamin
D
*Limitations (risk of bias). †Inconsistency. ‡Imprecision. §Severe imprecision. ¶Contributing direct evidence of moderate quality. **Contributing direct evidence of
low or very low quality. ††Cannot be estimated because the drug was not connected in a loop in the evidence network. ‡‡Indirectness because of questionable
comparability of trial populations to target population of NMA (postmenopausal women) or because of intransitivity. §§Greater precision.
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Table 2| Illustration of coherence and incoherence from a network meta-analysis of alternative surgical approaches to open tibial fractures
Network meta-analysisIndirect evidenceDirect evidence
Comparison
Quality of
evidence
Odds ratio (95%
credible interval)
Quality of
evidence
Odds ratio (95%
credible interval)
Quality of
evidence
Odds ratio (95%
confidence interval)
⊕⊕ΟΟ§ Low0.62 (0.37 to 1.03)⊕⊕ΟΟ†,‡ Low0.07 (0.01 to 0.46)⊕⊕⊕Ο* Moderate0.74 (0.45 to 1.24)Unreamed v
reamed
⊕⊕⊕Ο Moderate0.38 (0.23 to 0.62)⊕⊕ΟΟ*,† Low0.35 (0.08 to 1.56)⊕⊕⊕Ο¶ Moderate0.39 (0.23 to 0.65)Unreamed v
external fixation
*Imprecision. †Contributing direct evidence of moderate quality. ‡Indirectness. §Incoherence. ¶Limitations (risk of bias).
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Figures
Fig 1 Approach for rating the quality of network meta-analysis (NMA) estimates
Fig 2 Evidence network of randomised trials comparing the effects of drugs to prevent osteoporotic hip fractures. The size
of the circle is proportional to the number of participants randomised to that treatment. Width of the lines is proportional to
the number of trials for that comparison. Coloured dashed lines refer to loops for indirect evidence (see text).
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